International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers
Pooling over 5,000 patients, the IGCCCG classification sorted metastatic testicular cancer into good, intermediate and poor prognosis groups using tumour markers, primary site and non-lung metastases, and still decides how many cycles of chemotherapy a man receives.
Overview
Analysis of 5,202 patients with metastatic non-seminomatous and 660 with seminomatous germ cell tumours treated with cisplatin-based chemotherapy, identifying tumour marker levels (AFP, hCG, LDH), mediastinal primary site and non-pulmonary visceral metastases as independent prognostic factors and defining good (56 percent, 92 percent five-year survival), intermediate (28 percent, 80 percent) and poor (16 percent, 48 percent) prognosis groups for non-seminoma.
- Good, intermediate and poor prognosis non-seminoma: five-year survival 92, 80 and 48 percent.
- Seminoma: good (86 percent) and intermediate (72 percent) groups by non-pulmonary visceral metastases.
Three cycles of BEP for good risk and four for intermediate and poor risk follow directly from this classification, which was updated in 2021 with modern survival figures.
- Survival figures predate modern supportive care; the 2021 update reports better outcomes in all groups.
Similar pages
not linked directly; found by shared links- Key paperIGCCCG Update Consortium: predicting outcomes in men with metastatic non-seminomatous germ cell tumours
Shares Non-seminomatous germ cell tumour, Journal of Clinical Oncology.
- Key paperSEMPET: FDG-PET as a predictor of viable tumour in post-chemotherapy seminoma residuals
Shares Seminoma, Journal of Clinical Oncology.
- TechnologyAFP, hCG and LDH in germ cell tumours (IGCCCG risk groups)
- TreatmentBleomycin
- CancerTesticular germ cell tumours